Highly efficient anti-tfpi antibody composition
AssigneeThe Green Cross Corporation
InventorsMin Jung KIM, Geun Hye YEO, Haeng Eun SONG, Ji Yoon PARK, Yuna KIM
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Green Cross Corporation
InventorsMin Jung KIM, Geun Hye YEO, Haeng Eun SONG, Ji Yoon PARK, Yuna KIM
Estimating the term…
The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the content of LPA in the drug substance or the drug product is less than 1.0 ng/mg. According to the present disclosure, a highly efficient anti-TFPI antibody composition having very low contents of HCP and LPA may be provided by providing a separation/purification process capable of minimizing anti-TFPI antibody polymer generation, and may be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease.
A pharmaceutical composition comprising an anti-tissue factor pathway inhibitor (anti-TFPI) antibody, a content of host cell protein (HCP) is less than 10.0 ng/mg, and a content of leachable protein A (LPA) is less than 1.0 ng/mg.
A method of preparing a pharmaceutical composition comprising a purified anti-tissue factor pathway inhibitor (anti-TFPI antibody), wherein a content of host cell protein (HCP) in the composition is less than 10.0 ng/mg, and a content of leachable protein A (LPA) in the composition is less than 1.0 ng/mg,
Dependencies are inferred from the claim text.